Overview

A Study of Isoquercetin in People With Ovarian Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2032-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Phase:
PHASE2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Institutes of Health (NIH)
Treatments:
isoquercitrin